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Summary Background: Asthma and chronic obstructive pulmonary disease (COPD)
are highly prevalent chronic diseases characterized by airflow limitation. Both
diseases have a distinct pathogenesis and require unique treatment approaches. Due
to some common characteristic traits, asthma and COPD are often lumped together
in clinical practice. We sought to develop a simple questionnaire for the distinction
of asthma and COPD.
Methods: Clinical discriminants of asthma and COPD were retrospectively
identified by multiple logistic regression using files from 547 consecutive adult
patients presenting to a pulmonary specialist practice with a diagnosis of asthma or
COPD. With these features, we generated a simple quantitative questionnaire
supporting a diagnosis of COPD with high scores and asthma with low scores (range 0–
15 points). Questionnaire results were compared with physician’s diagnosis based on
GINA and GOLD guidelines including skin tests, spirometry and reversibility data.
Results: 210 patients had COPD and 337 had asthma. Age of onset, smoking history,
atopy status, and cough quality were significantly associated with a diagnosis of
asthma or COPD. Questionnaire scores for COPD patients were higher than those for
asthmatics (mean score 10.570.18 vs. 470.12, Po0:0001). Receiver operational
characteristics (ROC) analysis revealed a cutoff score of 7 with the highest
discriminant power (87.6% sensitivity, 87.2% specificity for COPD, 87.4% correctly
classified, area under the ROC curve: 0.954). The overlap between asthma and COPD
(score 6–8) comprised about 20% of the total population, these patients included a
higher proportion of COPD patients with atopy, and smoking asthmatics.
Conclusions: In patients with obstructive airway diseases, a simple questionnaire
can support the differentiation of asthma and COPD in everyday clinical practice.
Further prospective trials are necessary to confirm these initial observations.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Asthma and chronic obstructive pulmonary disease
(COPD) are inflammatory disorders characterized
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physiological similarities, both diseases represent
distinct entities comprising unique features with
regard to the underlying inflammatory pattern, the
involved mechanisms of airway obstruction, disease
progression and prognosis. These differences are
also reflected by distinct treatment recommenda-
tions, with a clear primacy of anti-inflammatory
treatment, e.g. inhaled corticosteroids, in asthma,
and bronchodilators in COPD. Moreover, anti-choli-
nergics are recommended as first-line bronchodila-
tors in COPD,1 whereas their use in asthma is of
minor importance.2 In view of the critical impor-
tance of choosing optimal treatment regimen for
both diseases with regard to both efficacy and also
health resource utilization, a clear distinction of
asthma and COPD in everyday practice would be
highly desirable. However, both diseases are often
lumped together in clinical practice, possibly due
to physician’s unawareness and lack or underuse of
spirometry.3–7 Moreover, there is also a consider-
able degree of overlap between asthma and COPD,
as indicated by recent analyses using large data-
bases in the UK and USA.8 Finally, the fact that
‘‘COPD’’ is an umbrella diagnosis encompassing
both chronic bronchitis and/or emphysema may
further complicate the differentiation of asthma
and COPD. Despite this, it is possible to classify the
majority of patients into the two categories of
asthma or COPD.
With this as background, we aimed to identify
clinical features of asthma and COPD with discri-
minant power using a large database from a
pulmonary specialist located in the inner city of
Frankfurt, Germany. Based on such parameters, we
hypothesized that it would be possible to generate
a simple questionnaire including a scoring system.
To evaluate this questionnaire, scores from the
questionnaire were retrospectively compared with
a ‘‘gold standard’’, i.e. a pulmonary specialist
diagnosis of asthma or COPD based on GINA and
GOLD recommendations including skin test results
and pulmonary function tests.
Methods
Patients
Data from a database including files from 1434
patients newly admitted to a pulmonary specialist
in the city of Frankfurt, Germany, between 1995
and 1996 were reviewed retrospectively.9 Due to
the German health care system, the practice then
had approximately 40% of self-referred patients,
and 60% of physician referrals, being largely
representative for other pulmonary specialist prac-
tices in that area. All files included information
about patient history, smoking habits, occupation,
age at onset of symptoms, atopy status or history of
atopic diseases, absence or presence of cough and
sputum, and dyspnea variability including triggers.
Diagnostic measurements that supported the spe-
cialist’s diagnosis included pulmonary function
tests (spirometry and bodyplethysmography using
Masterlab II equipment from Jaeger, Wuerzburg,
Germany, with forced expiratory volume in one
second [FEV1], forced vital capacity, and broncho-
dilator reversibility to 400 mg of salbutamol10) and
skin prick tests with standard allergens11 (Bencard,
Neuss, Germany).
A diagnosis of COPD was based on the criteria
proposed by the GOLD guidelines including typical
symptoms, exposure to risk factors, and/or char-
acteristic changes in lung function. GOLD staging
was based on post-bronchodilator spirometry para-
meters. In particular, stage 0 COPD was diagnosed
in patients exposed to irritants, e.g. active or
passive smoking, who presented with chronic
symptoms of cough and/or sputum production for
at least 3 months.1
A diagnosis of asthma was based on the following
criteria, that were adopted from GINA guidelines:12
(1) airflow obstruction (FEV1o85%) with reversi-
bility412% and at least 200ml from baseline after
bronchodilation or (2) positive histamine challenge
combined with typical clinical signs like dry cough
and wheezing in absence of acute respiratory tract
infection and positive atopy status.13
Diagnoses of COPD and asthma had been primar-
ily made by a pulmonary specialist (MK) and were
subsequently analyzed by another reviewer (KMB)
to confirm the initial diagnosis.
Clinical parameters
Based on availability from patient files, and a
presumed discriminant power, five clinical para-
meters were chosen for multiple regression analy-
sis. These included age at onset of symptoms, atopy
status (yes/no), smoking history and packyears,
variability of symptoms (constant/diurnal variation
and/or triggers), and cough characteristics (none/
dry/productive).
Questionnaire
Building on the results of the regression analysis, a
questionnaire including four items (age of onset,
smoking history, atopy status and cough quality)
was generated. Accordingly, each item was
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assigned a quantitative score (age of onset: o20
years¼ 0 points, 20–40 years¼ 1 point, 40–60
years¼ 2 points, 460 years¼ 3 points; atopy:
yes¼ 0 points, none¼ 4 points; smoked packyears:
0¼ 0 points, 40o20 packyears¼ 1 point, 20–40
packyears¼ 2 points, 440 packyears¼ 4 points;
cough characteristics: dry cough¼ 0 points, no
cough¼ 2, productive cough¼ 4 points). Hence,
patients had scores ranging from 0 to 15 points. The
score was aimed at preferably indicating COPD with
high scores and asthma with low scores.
Statistical analysis
Statistical analysis was performed using the STATA
5.0 intercooled software package (Stata Corp.,
College Station, TX, USA) for personal computer.
Descriptive data are presented as mean values with
standard error of mean (7SEM). Kolmogorov–Smir-
nov-Test was used to test variables for normal
distribution. Group comparisons were performed by
Mann–Whitney U-test or Student-t-test depending
on normal distribution. For multiple comparison,
repeated analysis of variance followed by Newman–
Keuls was used. Categorical data were compared by
Fisher–Exact-test. Correlations were calculated by
Spearman’s correlational analysis (rho).
Clinical parameters associated with a diagnosis of
either asthma or COPD were identified by multiple
regression analysis controlling for actual age and
sex, and presented as odds ratios (OR) with 95%
confidence intervals. Age of onset and smoking
were also separately analyzed after generating
categories for onset age and packyears, to allow a
more quantitative assessment of these parameters.
Finally, receiver operational characteristics (ROC)
were generated to compare discriminant values of
single and combined questionnaire items by calcu-
lating the ROC area under the curve (AUC) and the
corresponding values for sensitivity/specificity. P-





Among 1434 consecutive patients newly admitted
to the practice in 1995, 580 subjects (40%) had a
diagnosis of asthma or COPD and were eligible for
analysis. Of these, 33 subjects were aged under 18
and therefore excluded from the analysis, since
COPD does not occur in children or adolescents. Of
the remaining 547 patients, 210 had COPD and 337
asthma (Table 1). In COPD, 37% of patients had
stage 0 (‘‘at risk’’), 5% stage 1 (mild COPD), 46%
stage 2 (moderate COPD) and finally, 12% stage 3
disease (severe COPD). Using the GINA classification
of 1994,12 56% of asthmatics had intermittent or
mild persistent asthma, 27% moderate persistent,
and 17% severe asthma.
Other frequent diagnoses in the database were
acute upper respiratory tract infections (25%), sole
allergic rhinitis (6%), lung cancer (4%), interstitial
lung diseases (2%), and pneumonia (2%). About 15%
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Table 1 Characteristics of patients with asthma and COPD.
Asthma COPD P value
N ¼ 337 N ¼ 210
Age (median, range) 33 (18–76) 55 (20–82) o0.0001
Age at onset (median, range) 31 (8–73) 54 (20–82) o0.0001
Sex (male, %) 43 60 0.0008
Atopy (%) 75 14 o0.0001
Current smokers (%) 28 68 o0.0001
Packyears (median, range) 0 (0–40) 30 (0–150) o0.0001
Cough quality
None (%) 13 18 NS
Dry (%) 65 37 o0.0001
Productive (%) 10 45 o0.0001
Symptom variability
Diurnal variation (%) 66 58 NS
Constant (%) 34 42 NS
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of all patients had no medical diagnosis (check-up
consultation or non-specific symptoms).
Multiple logistic regression analysis
All items primarily chosen for the analysis were
significantly associated with a diagnosis of COPD or
asthma, except for symptom quality (Table 2). AUC
(ROC) values for each item were highest for smoked
packyears (0.93), followed by age of onset (0.84),
atopy status (0.80), cough characteristics (0.68)
and symptom quality (0.58).
After adjustment for sex in a separate regression
analysis, smoked packyears and age of onset
showed an increasing likelihood (OR) of being
diagnosed COPD with increasing age and packyears
(Figs. 1(a) and (b)). Accordingly, early onset of
symptoms (ageo20) and never smoking dramati-
cally increased the likelihood of an asthma diag-
nosis.
Questionnaire scores
Based on the results of the regression analysis
indicating no discriminant value, symptom quality
was deleted from the questionnaire. Using the
remaining four items, COPD patients had signifi-
cantly higher mean questionnaire scores than
patients with asthma (10.570.19 vs. 470.12,
Po0:0001) as indicated in (Fig. 2). Questionnaire
scores also tended to increase with increasing
severity of COPD, but this observation did not
reach statistical significance (P40:2; all compar-
isons). Moreover, scores were not linked to pre-
bronchodilator airway obstruction in asthma
patients (rho¼0.09, P ¼ 0:09). ROC analysis
revealed a high discriminative power of the
questionnaire (AUC-ROC: 0.954, 87.4% correctly
classified) as shown in (Fig. 3) with 87.6% sensitivity
and 87.2% specificity for a diagnosis of COPD using a
cutoff of 7 points. However, there was a consider-
able group of patients with scores between 6 and 8,
indicating an overlap population with no clear
distinction between asthma and COPD. In particu-
lar, this group included COPD patients with positive
skin tests (44% vs. 9% in ‘‘pure’’ COPD, Po0:001)
and increased bronchodilator reversibility, as
shown in Fig. 4(a). This group also included
predominantly non-allergic asthmatics (10% posi-
tive skin tests vs. 98% in ‘‘pure’’ asthma, Po0:001)
with heavier smoking as indicated in Fig. 4(b).
Discussion
The results from our study clearly indicate that by
means of a simple questionnaire the majority of
patients presenting to a practice with a suspected
or established diagnosis of obstructive airway
diseases can reliably be labelled as asthmatic or
COPD patient. Both asthma and COPD are highly
prevalent chronic airway diseases with increasing
global burden, and although proper discrimination
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Table 2 Multiple logistic regression analysis and
odd ratios (OR) with 95% confidence intervals for a
diagnosis of COPD.
OR 95% CI
Age at onset 1.13 1.1–1.6
Male sex 2.6 1.4–5.1
Current smoking 19.5 8.6–44.2
Atopy 0.04 0.02–0.08
Productive cough 6.2 4–23
Lack of symptom variability 1.5 0.8–2.8
Figure 1 (a)–(b) ORs and 95% confidence intervals (adjusted for gender) for a diagnosis of COPD with increasing
packyears (a), or age at onset of symptoms (b).
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is important for the optimal treatment choice, both
diseases are often lumped together in everyday
practice. The use of such a simple questionnaire
may therefore aid practitioners when distinguishing
between asthma and COPD.
Clearly, there are several limitations of our study.
Firstly, data were analyzed in a retrospective
fashion. Secondly, the setting of this study does
not fully preclude the possibility of a selectional or
referral bias, since it was performed in a pulmonary
specialist practice. Hence, the results may not
necessarily apply to a GP’s practice, thus limiting
the generalizability of our findings. However, our
approach also offers several advantages for a pilot
study. A substantial number of patients was
analyzed in a short period of time, and the setting
of a pulmonary specialist practice also allowed a
reliable diagnosis of asthma and COPD, that was as
close as possible to a ‘‘gold standard’’, i.e. the
diagnosis was supported by history, spirometry
including bronchodilator response and skin
test results for nearly all patients under survey.
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Figure 2 (a)–(b) Questionnaire mean scores (a) in patients with asthma and COPD, and frequency distribution (b) of
score categories. *Po0:001 vs. asthmatics.
Figure 3 ROC for questionnaire scores indicating a
diagnosis of asthma or COPD. AUC-ROC¼ 0.954, cutoff
47 points.
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Nevertheless, when using the questionnaire, there
was no clear distinction between both entities in a
considerable amount of patients, and this observa-
tion fits well into clinical experience, where
asthma and COPD, or at least their clinical and
physiological features, may be present in the same
patient,14,15 in particular in asthmatics who
smoke.16 In our population, COPD patients with
lower scores had clinical features of asthma, e.g.
some degree of atopy, whereas COPD patients with
high scores represented those with lowest reversi-
bility and more severe disease.
The degree of overlap between asthma and COPD
in our population was about 20% of all patients. This
finding concurs with recent data from the general
practice research database and the NHANES III trial
in the US,8 where between 17% and 19.1% of
patients had overlapping features. These authors
further distinguished between chronic bronchitis
and emphysema. However, a diagnosis of emphy-
sema was based solely on the fact, that a patient
had ‘‘ever been told to have emphysema by his
doctor’’. Given the fact, that the medical term
‘‘emphysema’’ is an anatomical diagnosis that
should be ideally confirmed by imaging techniques,
e.g. high-resolution CT, we decided rather to use
COPD as an umbrella diagnosis for chronic bron-
chitis and/or emphysema, as proposed by GOLD
guidelines. Diffusion capacity has also been pro-
posed as a marker for emphysema, but this
procedure was not performed in the majority of
our patients (in particular in asthmatics), hence we
abstained from further including emphysema as a
separate entity. Despite these problems, it is
apparent that the distinction of asthma and COPD
is not an artificial one for the majority of patients.
Further, it is clear that our analysis only focussed
on patients with an established diagnosis of
obstructive airway disease. We did not evaluate
patients presenting with respiratory symptoms
attributable to other respiratory or non-respiratory
diseases, e.g. pulmonary fibrosis or cardiac failure.
Obviously, it was not intended to use the presented
questionnaire as a diagnostic instrument (e.g. for
case detection or screening). In contrast, the
questionnaire was merely designed to eliviate the
differentiation of asthma and COPD, once a chronic
obstructive airway disease has been diagnosed.
Finally, the selection of clinical parameters to
develop a questionnaire was primarily an arbitrary
one grounded on availability, the author’s experi-
ence and published typical features.1,17–19 It
remains to be determined, whether the addition
or substitution of items would improve the dis-
criminative power of our tool. It also remains
speculative, whether the addition of reversibility,
e.g. assessed by peak flow measurements or
spirometry, would further add to diagnostic accu-
racy. Undoubtedly, spirometry or peak flow mea-
surements are pivotal tools for case detection in
general or risk population surveys, as demonstrated
previously.20,21 The combination of spirometry or
peak flow with bronchodilator reversibility testing
also serves as a guidance to distinguish asthmatics
from COPD patients by means of an objective
physiological response. However, bronchodilator
reversibility is not a categorical variable, and may
vary considerably intraindividually when measured
at different timepoints.22 Further, there is a wide
distribution of bronchodilator responses even in
COPD,23 and many asthma patients as well as stage
0 COPD patients share the finding of normal
spirometry, thus the true diagnostic value of adding
reversibility tests remains to be assessed prospec-
tively. Finally, one of our primary aims in this pilot
study was simplicity, offering the physician a
support in decision making, that is easy to handle
and non-time consuming. Thus, in light of the
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Figure 4 (a)–(b) Cigarette consumption (packyears) (a), and bronchodilator responses (b) in COPD and asthma. (A)
‘‘pure’’ COPD (scoreX9); (B) COPD (scoreo9); (C) ‘‘pure’’ asthma (scoreo6); (D) asthma (scoreX6). *Po0:02 vs. (A),
**Po0:05 vs. (C).
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already high discriminative power of our question-
naire and a given amount of ‘‘true’’ overlap, we
believe that there is only limited room for
improvement by adding spirometry results.
Spirometry, however, should nevertheless be
always mandatory to support the initial diag-
nosis of an obstructive airway disease and guide
therapy.
In conclusion, the results of our pilot analysis
clearly indicate, that a reasonable distinction
between asthma and COPD in everyday practice
can be done for the majority of patients with
obstructive airway diseases, even without taking
into account results from spirometry or reversibility
testing. Questionnaire-based tools are of valuable
assistance and can be easily and readily performed.
These initial observations warrant confirmation in
prospective trials.
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